Potential Research Subject

 

1. IDIOPATHIC INTRACRANIAL HYPERTENTION TREATMENT TRIAL (IIHTT)

NORDIC is no longer accepting participants for the IIHTT study.  Recruitment has concluded for this study.  

LEARN MORE about the original study design.

LEARN MORE more about the resulting publications.

 

2. NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATY (NAION)

Quark Pharmaceuticals and NORDIC are collaborating on an investigational drug trial to evaluate a neuroprotection therapy for acute Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).  The trial is currently enrolling subjects who are 50-80 years old and have had sudden vision loss in one eye within the last 14 days.  The trial is being conducted by Neuro-Ophthalmologists in private practices and in hospitals around the United States. 

Click here if you have experienced recent, sudden vision loss in one eye and would like information on enrolling as a Subject.

Click here if you are an Eye Care Specialist and would like information on referring a patient to this trial.

 

3. PEDIATRIC OPTIC NEURITIS

The Pediatric Optic Neuritis Prospective Outcomes Study, a joint collaboration between NORDIC and the Pediatric Eye Disease Investigator Group (PEDIG), is now open to interested sites.  This observational data collection study is funded by the National Eye Institute and will determine our investigators' ability to enroll children with optic neuritis into a research protocol, and help us develop estimates of visual acuity outcomes in these children.  Treatment is at the discretion of the investigator. A small research payment is made to sites for each enrollment and follow up exam completed.  If you are interested in participating, please email pedig@jaeb.org for further details.  LEARN MORE

 

 

NORDIC Headquarters
Mount Sinai West
1000 10th Avenue
RM 11-C06
New York, NY  10019
 Phone:  212-636-3516
Email: INFO@NORDICCLINICALTRIALS.COM